Early Cytokine Signatures of Hospitalized Mild and Severe COVID-19 Patients: A Prospective Observational Study.
SARS-CoV-2
asymptomatic patient
early inflammation
proinflammatory cytokines
regulatory cytokines
Journal
Journal of inflammation research
ISSN: 1178-7031
Titre abrégé: J Inflamm Res
Pays: New Zealand
ID NLM: 101512684
Informations de publication
Date de publication:
2023
2023
Historique:
received:
09
03
2023
accepted:
18
05
2023
medline:
28
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
The severe manifestation of coronavirus disease 2019 (COVID-19) is known to be mediated by several cytokines and chemokines. The study aimed to compare the early cytokine profile of mild and severe COVID-19 patients to that with COVID-19-like symptoms and tested negative for Severe Acute Respiratory Syndrome Coronavirus-2 in the Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) test. This was a prospective, observational study on COVID-19 patients admitted to King Khalid University Hospital, King Saud University Medical City from June to November 2020. Clinical and biochemical data were collected from hospital charts. Blood samples were collected at the time of hospital admission to measure cytokines. A Cytokine and Growth Factor High-Sensitivity Array was used to quantitatively measure cytokines. The study included 202 RT-PCR-positive individuals and 61 RT-PCR-negative individuals. C-Reactive protein (CRP) and Interleukin-10 (IL-10) levels were found significantly elevated in the RT-PCR positive group compared to the RT-PCR negative group ( CRP and IL-10 levels were elevated in the RT-PCR positive group. People with severe COVID-19 had higher CRP and VEGF levels and lower IL-4 levels. Elevated IFN-γ and IL-10 levels were seen in mild COVID-19 cases and elevated level of MCP-1 was seen in severe COVID-19 cases when categorized according to the length of stay in the hospital.
Sections du résumé
Background
UNASSIGNED
The severe manifestation of coronavirus disease 2019 (COVID-19) is known to be mediated by several cytokines and chemokines. The study aimed to compare the early cytokine profile of mild and severe COVID-19 patients to that with COVID-19-like symptoms and tested negative for Severe Acute Respiratory Syndrome Coronavirus-2 in the Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) test.
Methods
UNASSIGNED
This was a prospective, observational study on COVID-19 patients admitted to King Khalid University Hospital, King Saud University Medical City from June to November 2020. Clinical and biochemical data were collected from hospital charts. Blood samples were collected at the time of hospital admission to measure cytokines. A Cytokine and Growth Factor High-Sensitivity Array was used to quantitatively measure cytokines.
Results
UNASSIGNED
The study included 202 RT-PCR-positive individuals and 61 RT-PCR-negative individuals. C-Reactive protein (CRP) and Interleukin-10 (IL-10) levels were found significantly elevated in the RT-PCR positive group compared to the RT-PCR negative group (
Conclusion
UNASSIGNED
CRP and IL-10 levels were elevated in the RT-PCR positive group. People with severe COVID-19 had higher CRP and VEGF levels and lower IL-4 levels. Elevated IFN-γ and IL-10 levels were seen in mild COVID-19 cases and elevated level of MCP-1 was seen in severe COVID-19 cases when categorized according to the length of stay in the hospital.
Identifiants
pubmed: 37377977
doi: 10.2147/JIR.S408663
pii: 408663
pmc: PMC10292607
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2631-2643Informations de copyright
© 2023 Alfadda et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Cell Death Dis. 2020 Nov 6;11(11):957
pubmed: 33159040
Biomol Ther (Seoul). 2014 Jan;22(1):1-9
pubmed: 24596615
Biol Sex Differ. 2021 Dec 20;12(1):66
pubmed: 34930441
Virology. 2006 Sep 30;353(2):474-81
pubmed: 16860835
Sci Rep. 2020 Dec 10;10(1):21697
pubmed: 33303843
Mol Med. 2020 Oct 29;26(1):97
pubmed: 33121429
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Adv Sci (Weinh). 2021 Aug;8(15):e2004433
pubmed: 34114369
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Proc Natl Acad Sci U S A. 2022 Mar 15;119(11):
pubmed: 35217532
J Biochem. 2013 Jan;153(1):13-9
pubmed: 23172303
Clin Transl Immunology. 2020 Nov 13;9(11):e1204
pubmed: 33209300
Trends Immunol. 2021 Jan;42(1):3-5
pubmed: 33214057
J Infect Public Health. 2021 Sep;14(9):1133-1138
pubmed: 34343963
J Leukoc Biol. 2020 Jul;108(1):17-41
pubmed: 32534467
Front Immunol. 2020 Jun 16;11:1446
pubmed: 32612617
Front Immunol. 2021 Nov 19;12:748291
pubmed: 34867975
Int J Mol Sci. 2022 Jul 19;23(14):
pubmed: 35887283
J Reprod Immunol. 2020 Nov;142:103213
pubmed: 33080435
Int J Mol Sci. 2022 Aug 10;23(16):
pubmed: 36012146
Eur Heart J. 2021 Jun 14;42(23):2270-2279
pubmed: 33448289
Mediators Inflamm. 2015;2015:387842
pubmed: 26424968
J Med Virol. 2020 Nov;92(11):2409-2411
pubmed: 32516845
Biomedicines. 2022 Sep 09;10(9):
pubmed: 36140343
Virus Res. 2020 Nov;289:198171
pubmed: 32979474
J Interferon Cytokine Res. 2022 Aug;42(8):444-448
pubmed: 35559721
J Allergy Clin Immunol. 2021 Jun;147(6):2098-2107
pubmed: 33894209
J Biol Regul Homeost Agents. 2020 Apr 07;34(2):339-343
pubmed: 32253888
Cytokine. 2021 Jan;137:155323
pubmed: 33045526
Cytokine Growth Factor Rev. 2020 Aug;54:62-75
pubmed: 32513566
Crit Rev Clin Lab Sci. 2020 Sep;57(6):389-399
pubmed: 32503382
Exploration (Beijing). 2021 Oct;1(2):20210051
pubmed: 35434726
Rev Med Virol. 2020 Sep;30(5):e2123
pubmed: 32648313
Front Public Health. 2020 Apr 29;8:152
pubmed: 32411652